321 related articles for article (PubMed ID: 29025684)
1. Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (≥65 Years) Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium).
Song C; Sukul D; Seth M; Dupree JM; Khandelwal A; Dixon SR; Wohns D; LaLonde T; Gurm HS
Am J Cardiol; 2017 Dec; 120(11):1926-1932. PubMed ID: 29025684
[TBL] [Abstract][Full Text] [Related]
2. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
[TBL] [Abstract][Full Text] [Related]
3. Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention.
Olier I; Sirker A; Hildick-Smith DJR; Kinnaird T; Ludman P; de Belder MA; Baumbach A; Byrne J; Rashid M; Curzen N; Mamas MA;
Heart; 2018 Oct; 104(20):1683-1690. PubMed ID: 29437885
[TBL] [Abstract][Full Text] [Related]
4. Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
Sukul D; Seth M; Dixon SR; Khandelwal A; LaLonde TA; Gurm HS
J Invasive Cardiol; 2017 Oct; 29(10):340-351. PubMed ID: 28420804
[TBL] [Abstract][Full Text] [Related]
5. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.
Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW
Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome.
Kim K; Lee TA; Ardati AK; DiDomenico RJ; Touchette DR; Walton SM
Pharmacotherapy; 2017 Aug; 37(8):877-887. PubMed ID: 28555946
[TBL] [Abstract][Full Text] [Related]
7. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
[TBL] [Abstract][Full Text] [Related]
8. Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor.
Molife C; Frech-Tamas F; DeKoven M; Effron MB; Karkare S; Zhu Y; Larmore C; Lu J; McCollam P; Marrett E; Vetrovec GW
J Med Econ; 2015; 18(11):898-908. PubMed ID: 26086414
[TBL] [Abstract][Full Text] [Related]
9. One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel.
Simeone JC; Molife C; Marrett E; Frech-Tamas F; Effron MB; Nordstrom BL; Zhu YE; Keller S; Murphy BR; Nair KV; Vetrovec GW; Page RL; McCollam PL
Am J Cardiovasc Drugs; 2015 Oct; 15(5):337-50. PubMed ID: 26359016
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
[TBL] [Abstract][Full Text] [Related]
11. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
[TBL] [Abstract][Full Text] [Related]
12. Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
Verlinden NJ; Coons JC; Iasella CJ; Kane-Gill SL
J Cardiovasc Pharmacol Ther; 2017 Nov; 22(6):546-551. PubMed ID: 28279076
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
[TBL] [Abstract][Full Text] [Related]
14. One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database.
Effron MB; Nair KV; Molife C; Keller SY; Page RL; Simeone JC; Murphy B; Nordstrom BL; Zhu Y; McCollam PL; Vetrovec GW
Am J Cardiovasc Drugs; 2018 Apr; 18(2):129-141. PubMed ID: 29222628
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System.
Coons JC; Iasella CJ; Chanas T; Wang N; Williams K; Boyd A; Lyons J; Eckardt J; Rihtarchik L; Merkel A; Chambers A; Lemon LS; Smith R; Ensor CR
Ann Pharmacother; 2017 Aug; 51(8):649-655. PubMed ID: 28438043
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM
Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508
[TBL] [Abstract][Full Text] [Related]
17. Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
Kudaravalli M; Althouse AD; Marroquin OC; Khandhar SJ; Sharbaugh MS; Toma C; Conrad Smith AJ; Schindler JT; Lee JS; Mulukutla SR
Int J Cardiol; 2016 Nov; 223():854-859. PubMed ID: 27592042
[TBL] [Abstract][Full Text] [Related]
18. Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.
Khan JN; Greenwood JP; Nazir SA; Lai FY; Dalby M; Curzen N; Hetherington S; Kelly DJ; Blackman D; Peebles C; Wong J; Flather M; Swanton H; Gershlick AH; McCann GP
J Am Heart Assoc; 2016 May; 5(6):. PubMed ID: 27247336
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
Damman P; Varenhorst C; Koul S; Eriksson P; Erlinge D; Lagerqvist B; James SK
Am J Cardiol; 2014 Jan; 113(1):64-9. PubMed ID: 24169009
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
